Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Peptide YY3-36 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Peptide YY3-36 | DRUG | - |
Inclusion Criteria: * BMI 27-35 kg/m2 Exclusion Criteria: * Women of childbearing potential
Top 20 of 32 competitors
Peptide YY3-36 is an investigational drug being studied for the treatment of obesity. It is a small molecule being developed by Pfizer, Inc. for use in metabolic conditions. The drug is currently in Phase 1 clinical development, meaning it is still being tested in early-stage trials to evaluate its safety and tolerability.
Peptide YY3-36 is being developed by Pfizer, Inc., a pharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 1 clinical development for the treatment of obesity.
Peptide YY3-36 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for the treatment of obesity, and its Phase 1 trial has been completed.
Peptide YY3-36 has been studied in one clinical trial, identified by the National Clinical Trial number NCT00331175. This Phase 1 trial, titled 'Safety, Toleration and Pharmacokinetics of Single Intravenous Doses of Peptide YY in Overweight Adults,' was completed in the United States and enrolled 31 participants.
Peptide YY3-36 is a specific form of the peptide hormone Peptide YY. The clinical trial for Peptide YY3-36, NCT00331175, studied the safety and pharmacokinetics of single intravenous doses of Peptide YY in overweight adults, indicating that Peptide YY3-36 is the active form being investigated.